Abstract Number: 1114 • 2017 ACR/ARHP Annual Meeting
Effects of Diacerein Controlled Release Tablets in Serum Uric Acid Reduction in Treating Subjects with Gout
Background/Purpose: The goal of gout treatment is to reduce serum uric acid (sUA) concentrations below the urate solubility limit. Diacerein is known as an oral…Abstract Number: 1115 • 2017 ACR/ARHP Annual Meeting
Long-Term Adherence to Urate-Lowering Therapy in Gout: Do Not Blame on the Patients
Background/Purpose: adherence to urate-lowering treatment (ULT) in patients with gout is reported to be lower than 50% in the first year and below 20% at…Abstract Number: 1116 • 2017 ACR/ARHP Annual Meeting
Management of Acute Gout in Hospitalized Patients and Risk Factors for Xanthine Oxidase Inhibitor (XOI) Discontinuation or Dose Reduction
Background/Purpose: Patients with gout frequently have multiple serious co-morbidities, take concomitant medications, and have complex clinical profiles, making treatment of acute flares in hospital settings…Abstract Number: 1117 • 2017 ACR/ARHP Annual Meeting
the Absolute Risk of Clinically Diagnosed Gout By Serum Uric Acid Levels – Results from 30 Years Follow-up of the Malmö Preventive Project Cohort in Southern Sweden
Background/Purpose: Hyperuricemia i.e. increased s-uric acid levels (s-UA), is established risk factor for clinical gout. Studies regarding the absolute and relative effect on population level…Abstract Number: 1118 • 2017 ACR/ARHP Annual Meeting
Diabetes and Gout: Real-World Evidence Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization
Background/Purpose: Gout and type 2 diabetes mellitus (T2DM) are common in the United States (US), but little is known about potential associations of T2DM and…Abstract Number: 1119 • 2017 ACR/ARHP Annual Meeting
Uncontrolled Gout Patients with Higher Heart Failure Hospitalization Rates in US
Background/Purpose: Gout is the most common form of inflammatory arthritis and is caused by elevated serum uric acid (sUA). Elevated sUA is associated with worsened…Abstract Number: 1121 • 2017 ACR/ARHP Annual Meeting
Allopurinol Treatment for Gout: How Long to Reach Serum Urate Goal?
Background/Purpose: Urate-lowering therapy (ULT) is essential in chronic gout management. For decades, allopurinol has remained the most frequently prescribed ULT. Reaching a goal of serum…Abstract Number: 1122 • 2017 ACR/ARHP Annual Meeting
Prevalence of Chronic Kidney Disease and Uncontrolled Serum Uric Acid Levels in US Adult Gout Population: Results from the National Health and Nutrition Examination Survey 2007–2012
Background/Purpose: Gout is the most common form of inflammatory arthritis, mainly caused by elevated serum uric acid (sUA) levels. The American College of Rheumatology guidelines…Abstract Number: 1123 • 2017 ACR/ARHP Annual Meeting
Random Urinary Uric Acid/Creatinine Ratio Is Useful in the Estimation of 24-Hour Urine Uric Acid Excretion in Patients with Gout
Background/Purpose: Gout is a chronic inflammatory disease resulted from hyperuricemia. The measurement of 24-hour urinary uric acid excretion is frequently used to evaluate disease status…Abstract Number: 1125 • 2017 ACR/ARHP Annual Meeting
Factors Associated with Acute Gouty Arthritis in Patients Hospitalized with Acute Coronary Syndromes and Congestive Heart Failure
Background/Purpose: Hyperuricemia and untreated gout appears to be independent prognostic markers for poor all-cause and coronary heart disease mortality in patients with recent acute myocardial…Abstract Number: 1127 • 2017 ACR/ARHP Annual Meeting
Replication of Genetic Association of Peroxisome Proliferator-Activated Receptor Gamma-1B with Gout in a New Zealand Polynesian Sample Set
Background/Purpose: Gout results from formation of monosodium urate (MSU) crystals in the presence of hyperuricemia. Genome wide association studies have provided significant insights into hyperuricemia,…Abstract Number: 1128 • 2017 ACR/ARHP Annual Meeting
Effect of Urate-Lowering Treatment on the Risk of Urolithiasis in People with Gout
Background/Purpose: Appropriate dose of urate-lowering therapy (ULT) is needed for gout patients to dissolve existing urate crystals to prevent acute gout attacks and reduce the…Abstract Number: 1129 • 2017 ACR/ARHP Annual Meeting
Impact of Diuretics on Urate Lowering Therapy in Patients with Gout: Analysis of an Inception Cohort
Background/Purpose: Diuretics have been associated with impaired response to allopurinol and refractoriness in gout, but whether this stills after new urate-lowering treatments (ULT) and treat-to-target…Abstract Number: 1130 • 2017 ACR/ARHP Annual Meeting
Can Alcohol Intake in Moderation Lower the Risk of Myocardial Infarction and Mortality Even Among Gout Patients?
Background/Purpose: Alcohol is a well-established risk factor for gout. However, more than 60 prospective studies have also shown that moderate alcohol intake is associated with…Abstract Number: 1131 • 2017 ACR/ARHP Annual Meeting
The Dietary Approaches to Stop Hypertension (DASH) and Mediterranean Diets and Risk of Gout in Women: 28-Year Follow-up of a Prospective Cohort
Background/Purpose: There is increasing recognition of a gout epidemic, exacerbated by an unhealthy diet and a sedentary lifestyle. Indeed, our recent study among men confirmed…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »